Dolutegravir, abacavir and lamivudine as HIV therapy

Bibliography

• Palella F, Baker R, Moorman A, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006;43:27-34
   PubMed Web of Science ®Google Scholar
• Nachega J, Parienti J, Uthman O, et al. Lower pill burden and once-daily dosing antiretroviral treatment regimens for HIV infection: a meta-analysis of randomized controlled trials. Clin Infect Dis. [ Epub ahead of print]
   Google Scholar
• Rockstroh J, Lennox J, De Jesus E, et al. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naïve HIV-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis 2011;53:807-16
   PubMed Web of Science ®Google Scholar
• Garrido C, de Mendoza C, Alvarez E, et al. Plasma raltegravir exposure influences the antiviral activity and selection of resistance mutations. AIDS Res Hum Retroviruses 2012;28:156-64
   PubMed Web of Science ®Google Scholar
• Fernández-Montero JV, Vispo E, Soriano V. Emerging antiretroviral drugs. Expert Opin Pharmacother 2014;15:211-19
   PubMed Web of Science ®Google Scholar
• Manzardo C, Gatell JM. Stribild® (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate): a new paradigm for HIV-1 treatment. AIDS Rev 2014;16:35-42
   PubMed Web of Science ®Google Scholar
• Shah B, Schafer J, De Simone J. Dolutegravir: a new integrase strand transfer inhibitor for the treatment of HIV. Pharmacotherapy 2013. [ Epub ahead of print]
   Google Scholar
• Min S, Sloan L, De Jesus E, et al. Antiviral activity, safety, pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults. AIDS 2011;25:1737-45
   PubMed Web of Science ®Google Scholar
• Min S, Song I, Borland J, et al. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother 2010;54:254-8
   PubMed Web of Science ®Google Scholar
• Reese M, Savina P, Generaux G, et al. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. Drug Metab Dispos 2013;41:353-61
   PubMed Web of Science ®Google Scholar
• Patel P, Song I, Borland J, et al. Pharmacokinetics of the HIV integrase inhibitor S/GSK1349572 co-administered with acid-reducing agents and multivitamins in healthy volunteers. J Antimicrob Chemother 2011;66:1567-72
   PubMed Web of Science ®Google Scholar
• van Lunzen J, Maggiolo F, Arribas J, et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis 2012;12:111-18
   PubMed Web of Science ®Google Scholar
• Stellbrink H, Reynes J, Lazzarin A, et al. Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study. AIDS 2013;27:1771-8
   PubMed Web of Science ®Google Scholar
• Walmsley S, Antela A, Clumeck C, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med 2013;369:1807-18
   PubMed Web of Science ®Google Scholar
• Feinberg J, Clotet B, Khuong M, et al. Once-daily dolutegravir is superior to darunavir/ritonavir in antiretroviral naïve adults: 48-week results from FLAMINGO (ING114915) [abstract H-1464a]. 53rd ICAAC; 10 – 13 September 2013; Denver Colorado, USA
   Google Scholar
• Raffi F, Pozniak A, Wainberg M. Has the time come to abandon efavirenz for first-line antiretroviral therapy? J Antimicrob Chemother; In press
   Google Scholar
• Raffi F, Rachlis A, Stellbrink H, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet 2013;381:735-43
   PubMed Web of Science ®Google Scholar
• Cahn P, Pozniak A, Mingrone H, et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet 2013;382:700-8
   PubMed Web of Science ®Google Scholar
• Eron J, Clotet B, Durant J, et al. Safety and efficacy of dolutegravir in treatment experienced subjects with raltegravir resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis 2013;207:740-8
   PubMed Web of Science ®Google Scholar
• Castagna A, Maggiolo F, Penco G, et al. Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. J Infect Dis; In press
   Google Scholar
• Koteff J, Borland J, Chen S, et al. A Phase I study to evaluate the effect of dolutegravir on renal function via measurement of iohexal and para-amino-hippurate clearance in healthy subjects. Br J Clin Pharmacol 2013;75:990-6
   PubMed Web of Science ®Google Scholar
• Curtis L, Min S, Nichols G, et al. Once-daily dolutegravir (DTG; GSK1349572) has a renal safety profile comparable to raltegravir (RAL) and efavirenz in antiretroviral-naive adults: 48-week results from SPRING-2 (ING113086) and SINGLE (ING114467) [abstract TUPE282]. 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 30 June – 3 July 2013; Kuala Lumpur, Malaysia
   Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available from: http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf [Last accessed 10 March 2014]
   Google Scholar
• Sabin C. Abacavir use and the risk of myocardial infarction in the D:A:D study [abstract 747LB]. 21st CROI; 2 – 5 March 2014; Boston, MA
   Google Scholar
• Blanco J, Varghese V, Rhee S, et al. HIV-1 integrase inhibitor resistance and its clinical implications. J Infect Dis 2011;203:1204-14
   PubMed Web of Science ®Google Scholar
• Garrido C, Villacian J, Zahonero N, et al. Broad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens. Antimicrob Agents Chemother 2012;56:2873-8
   PubMed Web of Science ®Google Scholar
• Garrido C, Soriano V, Geretti AM, et al. Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients - impact of HIV subtypes and prior raltegravir experience. Antiviral Res 2011;90:164-7
   PubMed Web of Science ®Google Scholar
• Sax P, Tierney C, Collier A, et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med 2009;361:2230-40
   PubMed Web of Science ®Google Scholar
• Soriano V, McMahon B. Strategic use of lamivudine in the management of chronic hepatitis B. Antiviral Res 2013;100:435-8
   PubMedGoogle Scholar
• De Jesus E, Rockstroh J, Lennox J, et al. Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: week-192 overall and subgroup analyses from STARTMRK. HIV Clin Trials 2012;13:228-32
   PubMedGoogle Scholar
• Steigbigel R, Cooper D, Teppler H, et al. Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 phase III trials. Clin Infect Dis 2010;50:605-12
   PubMed Web of Science ®Google Scholar
• Lennox J, De Jesus E, Berger D, et al. Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr 2010;55:39-48
   PubMed Web of Science ®Google Scholar
• Vispo E, Mena A, Maida I, et al. Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C. J Antimicrob Chemother 2010;65:543-7
   PubMed Web of Science ®Google Scholar
• Eron J, Rockstroh J, Reynes J, et al. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infect Dis 2011;11:907-15
   PubMed Web of Science ®Google Scholar
• Vispo E, Barreiro P, Maida I, et al. Simplification from protease inhibitors to once- or twice-daily raltegravir: the ODIS trial. HIV Clin Trials 2010;11:197-204
   PubMed Web of Science ®Google Scholar
• Caby F, Bonmarchand M, Soulie C, et al. Efficacy of raltegravir once daily in switching strategies in HIV-1 infected patients with suppressed viremia [abstract BPD 1/7]. 14th European AIDS Clinical Society Conference; 16 – 19 October 2013; Brussels, Belgium
   Google Scholar
• Llibre J, Clotet B. Once-daily single-tablet regimens: a long and winding road to excellence in antiretroviral treatment. AIDS Rev 2012;14:168-78
   PubMed Web of Science ®Google Scholar